Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) EBT (2016 - 2026)

Champions Oncology has reported EBT over the past 17 years, most recently at -$237000.0 for Q1 2026.

  • For Q1 2026, EBT fell 105.25% year-over-year to -$237000.0; the TTM value through Jan 2026 reached -$2.4 million, down 137.46%, while the annual FY2025 figure was $4.6 million, 163.3% up from the prior year.
  • EBT for Q1 2026 was -$237000.0 at Champions Oncology, down from $255000.0 in the prior quarter.
  • Over five years, EBT peaked at $4.5 million in Q1 2025 and troughed at -$2.5 million in Q2 2023.
  • A 5-year average of -$466411.8 and a median of -$302000.0 in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: tumbled 102900.0% in 2023 and later surged 279.36% in 2025.
  • Year by year, EBT stood at -$2000.0 in 2022, then tumbled by 102900.0% to -$2.1 million in 2023, then surged by 135.87% to $739000.0 in 2024, then plummeted by 65.49% to $255000.0 in 2025, then plummeted by 192.94% to -$237000.0 in 2026.
  • Business Quant data shows EBT for CSBR at -$237000.0 in Q1 2026, $255000.0 in Q4 2025, and -$452000.0 in Q3 2025.